MIT

Trizzino joins Immunovaccine as CEO

Monday, September 12, 2011 12:44 PM

Immunovaccine has named John J. Trizzino chief executive officer, effective October 1, 2011. Trizzino will also be appointed to the company's board of directors.

More... »

Pfizer to create 400 jobs in Massachusetts

Friday, September 2, 2011 10:50 AM

Pfizer is gobbling up some prime biotech real estate in Cambridge, MA. The New York-based pharma company is adding space for 400 employees at the heart of the biotech R&D hub in Kendall Square, according to Xconomy Boston.

More... »

CROs using backlog numbers to put positive spin on less-than-stellar quarterly earnings reports

Monday, August 22, 2011 08:00 AM

Using backlog allows CROs to put a positive spin on what otherwise might be less-than-stellar earnings; while they may not have had the healthiest quarter—or year—financially, they can showcase all of the work that has been promised over the next few quarters in millions, or billions, of dollars.

More... »

DecisionView to launch enrollment-centric metrics

Monday, August 15, 2011 08:00 AM

Clinical trial enrollment-focused software maker DecisionView is launching what it says will be the first benchmarking effort to focus tightly on enrollment metrics.

More... »

GSK signs two-year pact with MolMed

Monday, August 8, 2011 11:49 AM

GlaxoSmithKline's efforts to tackle a rare and often deadly immune deficiency are making progress following a deal signed with Italy's MolMed, according to PharmaTimes.

More... »

Cetero says FDA’s actions ‘difficult to understand’—company notified agency of chemists’ misconduct

Monday, August 1, 2011 08:02 AM

Large, early-phase CRO Cetero Research seemed blindsided by the FDA’s letter to the company last week accusing it of falsifying data and manipulating samples over a five-year period at its Houston bioanalytics lab.

More... »

GSK CEO predicts R&D success

Friday, July 29, 2011 10:08 AM

GlaxoSmithKline CEO Andrew Witty said the pharmaceutical industry would contract in coming years and that the survivors would be those companies that solved the "equation" of how to squeeze the most profit from every dollar spent on R&D, according to the Philadelphia Inquirer.

More... »

Rebecca Kush to serve on HITS Standards Committee

Wednesday, July 20, 2011 11:48 AM

Rebecca Daniels Kush has been invited to serve on the HIT Standards Committee, a federal advisory committee that makes recommendations to the national coordinator on standards, implementation specifications and certification criteria for the electronic exchange and use of health information for the purposes of adoption, consistent with the implementation of the Federal Health IT Strategic Plan, and in accordance with policies developed by the HIT Policy Committee.

More... »

Upsher-Smith launches phase III epilepsy study

Wednesday, July 20, 2011 11:08 AM

Upsher-Smith Laboratories initiated a phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted Orphan Drug designation for this use by the FDA.

More... »

FDA approves Whooping Cough vaccine

Monday, July 11, 2011 12:24 PM

The FDA has approved GlaxoSmithKline’s BOOSTRIXR [Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed (Tdap)] for use in adults 65 years of age and older for active booster immunization against tetanus, diphtheria and pertussis (whooping cough). This approval makes BOOSTRIX the first Tdap vaccine approved for use in this age group.

More... »